IQST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
iQSTEL Inc (IQST) shows mixed signals for a long-term investment. While the company has demonstrated revenue growth and plans for significant expansion, its recent financial performance, including a negative EPS and missed expectations, raises concerns. The technical indicators suggest the stock is currently overbought, and there are no strong proprietary trading signals or significant trading trends to support a buy decision. Given the user's beginner status, long-term focus, and impatience, it is recommended to hold off on purchasing this stock until clearer positive trends emerge.
The MACD is positively expanding, indicating bullish momentum, but the RSI at 77.162 suggests the stock is overbought. Moving averages are converging, showing no clear trend. Key resistance levels (R1: 2.144, R2: 2.338) have been surpassed, but the stock may face difficulty sustaining its current price level.
The company has signed an MOU to enter the digital health market, which could open new revenue streams. Revenue grew by 11.9% in 2025, and stockholders' equity increased by 37%. The company has ambitious plans to reach $1 billion in annual revenue within 24 months.
The FY 2025 GAAP EPS of -$2.86 missed expectations, and revenue of $316.9 million fell short of market forecasts. Q4 revenue dropped by 14.83% YoY, and the company's profitability remains under pressure. The stock's recent price surge may not be sustainable, given the lack of strong trading trends or insider activity.
In Q4 2025, revenue dropped by 14.83% YoY to $84.2 million. Net income improved by 33% YoY but remained negative at -$3.83 million. EPS increased significantly but stayed negative at -2.86. Gross margin improved by 28.62% YoY to 3.46%, indicating some operational efficiency gains.
No analyst rating data available. Wall Street sentiment appears cautious due to the company's financial challenges and missed expectations.
